Key Takeaways
- The company elevated its annual revenue projection to $3.1B-$3.3B, surpassing Wall Street’s $2.93B forecast
- Second quarter revenue reached $753.2M, exceeding expectations, though the firm reported a $0.37 per share loss versus the anticipated 5-cent deficit
- HIMS shares declined approximately 7% during Tuesday’s premarket session following a 5.5% drop in Monday’s after-hours trading
- Profit margins contracted for a fourth consecutive quarter amid rising expenses, with overall operational costs jumping 48% compared to last year
- Restructuring expenses continue as the business transitions away from compounded GLP-1 medications toward FDA-approved branded weight management products
Despite delivering a significantly upgraded 2026 revenue forecast that exceeded analyst projections Monday evening, Hims & Hers Health witnessed shareholder enthusiasm evaporate. The telehealth provider’s shares tumbled 5.5% during extended trading Monday and continued sliding nearly 7% in Tuesday’s premarket session.
Hims & Hers Health, Inc., HIMS
Management now anticipates annual revenue landing between $3.1 billion and $3.3 billion, representing an upward revision from the previously stated $2.8 billion to $3 billion range. The company’s third-quarter outlook of $880 million to $900 million similarly exceeded the $792.2 million consensus among analysts.
Second-quarter revenue totaled $753.2 million, surpassing FactSet’s $698.9 million consensus estimate. The platform welcomed over 300,000 new subscribers during the three-month period.
However, the impressive topline figures couldn’t conceal deeper profitability concerns. The business recorded a $0.37 per share loss, dramatically wider than the $0.05 deficit Wall Street had anticipated.
Operational expenses jumped 48% year-over-year. Revenue-related costs more than doubled to reach $272.4 million, compressing gross profitability margins for a fourth straight quarter.
Chief Financial Officer Yemi Okupe addressed the profitability challenges directly during the analyst conference call. He indicated that gross margins would probably remain below historical benchmarks as branded weight management offerings and international operations constitute larger portions of total revenue.
Profitability Squeeze Connected to Weight-Loss Strategy Shift
The escalating cost structure stems directly from Hims’ strategic pivot away from compounded GLP-1 treatments. The company developed a rapidly expanding weight-loss segment using compounded semaglutide during supply shortages of Wegovy and Zepbound, though this approach is now ending.
In March, Hims reached a settlement agreeing to discontinue manufacturing its proprietary compounded GLP-1 medications after Novo Nordisk filed a patent infringement lawsuit. The organization is transitioning toward distributing FDA-approved branded alternatives, which command substantially higher procurement costs.
Management indicated that additional restructuring expenses related to this operational transformation are anticipated. The company reduced the upper boundary of its adjusted EBITDA projection for the year, despite simultaneously raising revenue expectations.
Leerink Partners analyst Michael Cherny captured the challenge: “We still see a tough balance between spending to grow and growth, keeping our optimism limited.”
Litigation Expenses Compound Financial Strain
Compounding the margin deterioration, Hims recorded $47.5 million in nonrecurring contingency expenses during the quarter. These reserves are earmarked for anticipated settlement payments associated with ongoing legal proceedings.
This encompasses a complaint filed approximately ten days ago by the Federal Trade Commission alongside multiple state authorities, alleging misleading privacy policies, undisclosed billing practices, and deliberately complicated cancellation procedures. Hims rejected the accusations as calculated “to generate headlines at our expense.”
CEO Andrew Dudum devoted considerable attention during his remarks to the company’s recently launched AI-powered clinical platform, describing it as fundamental to transforming the consumer healthcare journey. CFO Okupe attributed the upgraded guidance to AI-enabled operational improvements and international expansion momentum, including the acquisition of Eucalyptus, an Australian telehealth platform.
Barclays analyst Glen Santangelo suggested profitability could strengthen during the year’s latter half. Management maintains long-term targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030.
HIMS stock has declined approximately 2% year-to-date.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
